Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study

Drugs in Context

article

María Lainez¹  Iñigo Tejado²  Alfredo Yoldi³  Sonsoles Gutiérrez Medina⁴  Alfonso Soto⁵  Manuel A Botana⁶  Virginia Bellido⁷  Irene Caballero⁸  Cristóbal Morales^1,10  Juan Francisco Merino-Torres^1,11  Paloma Moreno-Moreno^1,12 

[1] Departamento de Endocrinología y Nutrición, Hospital Juan Ramón Jiménez;Departamento de Endocrinología y Nutrición, Hospital Sierrallana;Departamento de Endocrinología y Nutrición, Hospital Universitario de Donostia;Departamento de Endocrinología y Nutrición, Hospital Universitario Rey Juan Carlos;Departamento de Endocrinología y Nutrición, Hospital Universitario de A Coruña;Departamento de Endocrinología y Nutrición, Hospital Universitario Lucus Augusti;Departamento de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío;Unidad de Diabetes y Obesidad, Hospital Vithas Sevilla;Hospital Universitario Virgen Macarena;nidad de Diabetes y Obesidad, Hospital Vithas Sevilla;Departamento de Endocrinología y Nutrición, Hospital Universitario de la Fe;Departamento de Endocrinología y Nutrición, Hospital Universitario Reina Sofía

关键词: clinical practice;    dapagliflozin;    diabetes;    HbA1c;    weight;   

DOI  :  10.7573/dic.2021-11-5

学科分类：社会科学、人文和艺术（综合）

来源: C S F Medical Communications Ltd.

【 摘 要 】

Background: This study aims to evaluate dapagliflozin in patients with type 2 diabetes (T2D) in clinical practice in Spain. Methods: This is a retrospective study including adults with T2D under stable antidiabetic therapy, with either dapagliflozin or sitagliptin ≥6 months, before inclusion. Data about the effectiveness and safety of dapagliflozin are presented. Results: A total of 594 patients (61.8±9.9 years, 21.7% cardiovascular disease) were included. After 6 months, HbA1c, weight, blood pressure, urine albumin-to-creatinine ratio and uric acid significantly decreased (1.63%, 2.88 kg, 4.82/2.70 mmHg, −17.38 mg/g and −0.30 mg/dL, respectively), whereas glomerular filtration rate and haematocrit significantly increased (3.72 mL/min/1.73 m2 and 1.8%, respectively). No cases of hypoglycaemia, diabetic ketoacidosis, Fournier gangrene, fractures or amputations were reported. Conclusion: Thus, dapagliflozin provides a comprehensive cardiometabolic protection in patients with T2D.

【 授权许可】

CC BY-NC-ND